Medarex Announces Presentations at Annual Meeting of the American Society of Clinical...

Medarex Announces Presentations at Annual Meeting of the American Society of
Clinical Oncology

- Updated Survival and Biomarker Data for Ipilimumab to be Presented -

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq:
MEDX) announced today that the following clinical abstracts for ipilimumab in
melanoma and prostate cancer, as well as for an anti-PD-1 antibody for cancer
treatment, have been selected to be the subject of presentations at the Annual
Meeting of the American Society of Clinical Oncology, being held May 29-June
2, 2009 in Orlando:

Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

-- "Association of baseline and on-study tumor biopsy markers with
clinical activity in patients (pts) with advanced melanoma treated
with
ipilimumab" (Abstract #9008, Developmental Therapeutics:
Immunotherapy Session) O. Hamid - Oral presentation from 1:00 p.m. to
4:15 p.m. local time on Saturday, May 30, 2009.

-- "Increased humoral and cellular immunity in patients (pts) with
advanced melanoma treated with ipilimumab" (Abstract #3031,
Developmental Therapeutics: Immunotherapy Session) S. Parker - General
poster from 8:00 a.m. to 12:00 p.m. local time on Saturday, May 30,
2009.

-- "Effect of ipilimumab treatment on 18-month survival: update of
patients with advanced melanoma treated with 10 mg/kg ipilimumab in
three Phase II clinical trials" (Abstract #9033, Melanoma Session)
S. O'Day - Poster discussion from 8:00 a.m. to 12:00 p.m. local
time on Sunday, May 31, 2009.

-- "Immunologic impact of anti-CTLA-4 therapy" (Abstract #3019,
Development Therapeutics: Immunotherapy Session) P. Sharma - Poster
discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, May 31,
2009.

-- "Association of peripheral blood lymphocyte count (ALC) and
clinical activity in patients (pts) with advanced melanoma treated
with
ipilimumab" (Abstract #3020, Developmental Therapeutics:
Immunotherapy Session) D. Berman - Poster discussion from 2:00 p.m. to
6:00 p.m. local time on Sunday, May 31, 2009.

-- "Phase 2 trial of extended dose anti-CTLA-4 antibody ipilimumab
(formerly known as MDX-010) with a multipeptide vaccine for resected
stages IIIC and IV melanoma" (Abstract #9023, Melanoma Session) J.
Weber - Poster discussion from 8:00 a.m. to 12:00 p.m. local time on
Sunday, May 31, 2009.

-- "Evaluation of the effect of systemic corticosteroids for the
treatment of immune-related adverse events (irAEs) on the development
or
maintenance of ipilimumab clinical activity" (Abstract #9037,
Melanoma Session) A. Amin - General poster from 8:00 a.m. to 12:00
p.m.
local time on Monday, June 1, 2009.

-- "Association between immune-related adverse events (irAEs) and
disease control or overall survival in patients (pts) with advanced
melanoma treated with 10 mg/kg ipilimumab in three Phase 2 clinical
trials" (Abstract #9034, Melanoma Session) J. Lutzky - General
poster from 8:00 a.m. to 12:00 p.m. local time on Monday, June 1,
2009.

-- "Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients
(pts) with good and poor prognostic factors" (Abstract #9036,
Melanoma Session) J. Wolchok - General poster from 8:00 a.m. to 12:00
p.m. local time on Monday, June 1, 2009.

-- "Long-term survival in patients (pts) with advanced melanoma
treated with ipilimumab with or without dacarbazine" (Abstract
#9038, Melanoma Session) E. Hersh - General poster from 8:00 a.m. to
12:00 p.m. local time on Monday, June 1, 2009.

-- "Effect of ipilimumab at 10 mg/kg on disease control in patients
(pts) with M1c-stage melanoma in relation to baseline lactate
dehydrogenase (LDH) levels" (Abstract #9041, Melanoma Session) M.
Smylie - General poster from 8:00 a.m. to 12:00 p.m. local time on
Monday, June 1, 2009.

Response and Safety Data of Ipilimumab in Prostate

-- "Initial Phase 2 experience of ipilimumab (IPI) alone and in
combination with radiotherapy (XRT) in patients with metastatic
castration resistant prostate cancer (mCRPC)" (Abstract #5138,
Genitourinary Cancer - Prostate Session) S. Slovin - General poster
from
2:00 p.m. to 6:00 p.m. local time on Sunday, May 31, 2009.

-- "Phase 1 trial of targeted therapy with PSA-TRICOM Vaccine (V) and
ipilimumab (ipi) in patients (pts) with metastatic
castration-resistant
prostate cancer (mCRPC)" (Abstract #5144, Genitourinary Cancer
Session) M. Mohebtash - General poster from 2:00 p.m. to 6:00 p.m.
local
time on Sunday, May 31, 2009.

Clinical Data of MDX-1106 in Cancer

-- "Phase 2 experience with MDX-1106 (Ono-4538), an anti-PD-1
monoclonal antibody, in patients with selected refractory or relapsed
malignancies" (Abstract #3018, Developmental Therapeutics:
Immunotherapy Session) J. Brahmer - Poster discussion from 2:00 p.m.
to
6:00 p.m. local time on Sunday, May 31, 2009.

More information about the ASCO Annual Meeting may be found at www.asco.org.

About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development
and potential commercialization of fully human antibody-based therapeutics to
treat life-threatening and debilitating diseases, including cancer,
inflammation, autoimmune disorders and infectious diseases. Medarex applies
its UltiMAb(R) technology and product development and clinical manufacturing
experience to generate, support and potentially commercialize a broad range of
fully human antibody product candidates for itself and its partners. Over
forty of these therapeutic product candidates derived from Medarex technology
are in human clinical testing or have had INDs submitted for such trials, with
the most advanced product candidates currently in Phase 3 clinical trials, the
subject of regulatory applications for marketing authorization or approved for
commercial sale. Medarex is committed to building value by developing a
diverse pipeline of antibody products to address the world's unmet healthcare
needs. For more information about Medarex, visit its website at
www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.

SOURCE Medarex, Inc.

Laura S. Choi, Investor Relations, +1-609-430-2880, x2216; Nichol Ochsner,
Corporate Communications (media), +1-609-430-2880, x2214